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Tuberculosis (TB) is one of the oldest diseases known to affect human being. The first case was described in Egyptian mummies about 7000 years ago, when it was 
described as “Phthisis” by Hippocrates. It was estimated that 
about one-third of the world’s population is infected with the 
TB. Although India is the second-most populated country in 
the world, one-fourth of the global incident TB cases occurs 
annually here. The out of global annual incidence of 8.6 million 
TB cases in 2012, 2.3 million were estimated to have occurred 
in India [1]. As much as 75% of individuals with TB are within 
the economically productive age group of 15-54 years. This 
significantly impairs socio-economic development, thereby 
perpetuating the poverty cycle [2]. Clinical diagnosis of TB in 
pregnant women can be difficult due to nonspecific symptoms 
related to the physiological response to pregnancy [3]. The 
disease is responsible for killing more women of reproductive 
age than all the combined causes of maternal mortality [4]. The 
exact incidence of TB in pregnancy is not readily available in 
many countries due to a lot of confounding factors. It is expected 
that the incidence of TB among pregnant women would be as 
high as in the general population, with probably higher incidence 
in developing countries. It is best described as a double edged 
sword, one blade being the effect of TB on pregnancy and the 
pattern of growth of the newborn, while the other is the effect 
of pregnancy on the progression of TB. Untreated TB represents 
a greater hazard to a pregnant woman and her fetus than does 
its treatment. Treatment of pregnant women should be initiated 
whenever the probability of TB is moderate to high. Infants born 
to women with untreated TB may be of lower birth weight than 
those born to women without TB and, rarely, the infant may be 
born with TB. Although the drugs used in the initial treatment 
regimen cross the placenta, they do not appear to have harmful 
effects on the fetus. There is little evidence to guide clinicians in 
the treatment of drug-resistant TB in pregnancy.
Effect of Pregnancy on TB
The TB cavities may collapse as a result of the increased 
intra-abdominal pressure associated with pregnancy [5] and 
after that German physician observed that young women with 
pulmonary TB to get married to slow the progression of diseases. 
But in the 20th century, people believed that pregnancy has a 
deleterious effect on TB and to avoid that induced abortion was 
recommended for such type of problem [6]. TB is believed to get 
flared up by the stress of pregnancy, especially in association with 
a poor nutritional status, immunodeficient state, or co-existent 
diseases [7]. There are some studies which show that pregnancy 
has no positive or negative impact on TB [8]. Hedvall reported 
on 250 of his own pregnant patients and found that 9% improved, 
7% deteriorated, and 84% were unchanged antepartum, with 9% 
improving, 15% deteriorating and 76% remaining unchanged 
postpartum [9]. Studies in London in the 1950s by Pridie and 
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Stradling showed rates of TB in the pregnant population to be the 
same as in the nonpregnant population [10].
Effects of TB on Pregnancy
The effects of TB on pregnancy may be influenced by many factors, 
like severity of the disease, how advanced the pregnancy has gone 
at the time of diagnosis, the presence of extrapulmonary spread, 
and HIV coinfection and the treatment instituted. The pulmonary 
and extrapulmonary forms of TB effect pregnant women in the 
same way as the nonpregnant ones. If anti-TB treatment (ATT) 
is started early in pregnancy, the outcome is same as that in non-
pregnant patients, whereas late diagnosis and care are associated 
with 4-fold increase in obstetric morbidity and 9-fold increase in 
pre-term labor [11]. A higher frequency of abortion, toxemia, and 
intrapartum complications were reported in another series [12]. 
There is one Indian study which shows no increase in maternal 
mortality [13]. Other factors such as poor nutritional states, 
hypoproteinemia, anemia, and associated medical conditions 
add to maternal morbidity and mortality. The worst prognosis is 
recorded in women in whom a diagnosis of advanced disease is 
made in the puerperium as well as those with HIV coinfection. 
Other obstetric complications that have been reported in these 
women include a higher rate of spontaneous abortion, small for 
date uterus, and suboptimal weight gain in pregnancy [11].
Effect of TB on Perinatal Outcome
There are many reports of variable perinatal outcomes with 
increased abortion rates, high levels of pre-eclampsia, and 
increased levels of difficult labor requiring intervention in some 
studies [7] but overall good fetal outcome in others [12]. In a study 
of Indian women with pulmonary disease treated for 6-9 months 
in pregnancy, perinatal mortality was six times higher than in 
controls and the incidence of prematurity, small-for-date babies, 
and low birth weight (<2500 g) was doubled [14].
CONGENITAL TB
A fetus can get TB infection either by hematogenous spread 
through umbilical vein to fetal liver or by ingestion or aspiration 
of infected amniotic fluid [15].
True congenital TB is believed to be rare. The risk to neonate 
of getting TB infection shortly after the birth is greater [16,17]. 
A primary focus subsequently develops in the liver, with the 
involvement of the periportal lymph nodes. The tubercle bacilli 
infect the lungs secondarily, unlike in adults where over 80% of the 
primary infections occur in the lungs. Criteria given by Cantwell 
et al., for confirming fetal/neonatal TB comprise demonstration of 
either primary hepatic complex/caseating hepatic granulomas or 
percutaneous liver biopsy at birth or presence of maternal genital 
tract/placenta TB or the presence of lesions during first week of life 
by excluding postnatal transmission by a thorough investigation 
of all the contacts (including the attendants) [16]. The clinical 
presentations of congenital TB include hepatosplenomegaly, 
respiratory distress, fever, and lymphadenopathy. However, 
it is always challenges to differentiate from other congenital 
infections. The possibility of postnatal transmission must be 
excluded by a thorough investigation of all contacts, including 
hospital staffs and attendants. An abnormal chest radiograph is 
found in all such cases, half of whom have a miliary pattern [18]. 
The overall mortality for congenital TB is 38% in the untreated 
and 22% in the treated [18].
CLINICAL PRESENTATION
The clinical presentation of TB is similar to nonpregnant woman, but 
the diagnosis is often delayed due to non-specific early symptoms and 
has similar constitutional symptoms such as malaise and fatiguability 
found in pregnancy [19]. The most common site in pregnancy 
is pulmonary and, in a study, of the 27 pregnancies reported with 
culture-positive disease, 74% had cough, 41% had weight loss, 30% 
had fever, malaise or fatigue, and 19% had hemoptysis; 20% were 
asymptomatic but all had abnormal radiographs [19].
The diagnosis of pulmonary TB is also delayed due to delayed 
X-ray to avoid radiation toxicity and that investigation of sputum 
smear negative TB is more difficult [20]. Other studies have 
found less significant symptoms in pregnant women with TB.
DIAGNOSIS OF PULMONARY TB IN PREGNANCY
Diagnosis of TB based on Revised National Tuberculosis Control 
Program algorithm and all patients having a cough of more than 
2 weeks duration should undergo sputum examination for acid-
fast bacilli. At least two sputum samples should be processed for 
ZN-staining to detect acid-fast bacilli. Microscopic examination 
of sputum or another specimen by light-emitting diode (LED) 
fluorescent microscopy has recently been introduced to improve 
diagnosis. If the facilities for Gene-Xpert are there, the sample 
should be preferentially processed for detection Gene-Xpert 
along with ZN-staining. The gold standard for bacteriological test 
is culture which could be performed by solid L-J media or liquid 
mycobacteria growth indicator tube method.
TREATMENT
The main concern about TB treatment in pregnancy is the risk of 
teratogenicity specially in the 1st trimester.
PRINCIPLES
1. ATT should be started promptly as untreated disease presents 
a hazard to the mother and fetus.
2. The same regimens are recommended for use in pregnancy 
as for the nonpregnant state except for withholding of 
streptomycin.
3. A question-mark exists on the safety of second-line drugs in 
the pregnant state. Therefore, expectant mothers with multi-
drug resistance-TB (MDR-TB) should be advised to terminate 
the pregnancy. If a woman insists on its continuation, the 
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possible consequences of the same should be discussed with 
her in detail.
4. The management of pregnant TB women becomes 
complicated in the presence of HIV infection due to the 
involved drug interactions. Hence, the regimens and drug 
dosages need appropriate adjustments.
5. Pyridoxin should be given to all patients receiving Isoniazid 
to prevent peripheral neuropathy.
6. Newborn should be segregated from if she is having active 
pulmonary TB not on the treatment of receiving from 
<2 weeks.
7. Vitamin K should be given prophylactically to newborn at 
birth to prevent Hemorrhagic diseases of newborn.
8. Neonates born to mothers having infectious TB should be 
given chemoprophylaxis with isoniazid (INH) for 3 months 
or till the mother becomes noninfectious. Bacille Calmette-
Guérin (BCG) vaccination may be postponed or done with 
INH-resistant BCG vaccine.
ANTI-TB DRUGS
First-line Drugs
Isoniazid
Pregnancy category A - Recommended for use in pregnancy: 
Isoniazid has high lipid solubility, a low molecular weight, and 
crosses the placenta readily to reach fetal levels similar to those 
of the mother. As isoniazid may be associated with an increased 
risk of hepatotoxicity in pregnant women, symptoms should be 
assessed and it is recommended by some that liver function tests 
be performed fortnightly during the first 2 months of treatment, 
and monthly thereafter [21].
Rifampicin
Pregnancy Category C - Rifampicin is most powerful anti-TB 
drug readily absorbed after oral administration with a peak serum 
concentration of 5-7 mg/l within 1.5-2 h in nonpregnant subjects 
and good penetration into all tissues despite the fact that 75% is 
protein bound.
Bleeding attributed to hypoprothrominemia has been reported 
in infants and mothers following the use of rifampicin in late 
pregnancy. The use of rifampicin is indicated in pregnant women 
with TB, with the recommendation that vitamin K be given to 
both the mother and the infant postpartum if rifampicin is used in 
the last few weeks of pregnancy [21].
Ethambutol
Pregnancy Category A - Recommended for use in pregnancy.
Pyrazinamide
Pregnancy Category N/A - There are no reports of fetal malformations 
attributable to pyrazinamide, although there are additionally no 
animal or epidemiological studies reported to support the safety 
of this drug in pregnancy. The absence of such safety data is the 
reason that the CDC (USA) guidelines do not endorse pyrazinamide 
in pregnancy. Its use is supported by other TB authorities, including 
the IUATLD and the BTS. To date, there are no reports of significant 
adverse events from the use of this drug in the treatment of TB in 
pregnant women despite the fact that the drug is used as part of 
the standard regimen in many countries. However, additionally, 
insufficient data are available about the number of pregnant women 
treated for TB in these many settings. If the treating doctor elects 
not to use pyrazinamide, a 9 months regimen containing isoniazid 
and rifampicin throughout (supplemented by ethambutol until drug 
susceptibility results are available) is recommended.
Second-line Medications
Streptomycin has a well-established association with fetal 
ototoxicity and not recommended for the treatment of TB in 
pregnant women. There is no evidence of increased incidence of 
abnormalities in babies of mothers treated with fluoroquinolones. 
Animal studies of ciprofloxacin suggest that there is a risk of 
damage to articular cartilage and subsequent juvenile arthritis 
with short courses of treatment, and the possibility of joint 
damage with longer courses of treatment used for TB must be 
seriously considered [21]. Fluoroquinolones should only be used 
in pregnant women with TB where the benefits of treatment are 
judged to outweigh the potential risks, and the decision to use 
such drugs in this setting should only be made after discussion 
with clinicians experienced in the management of TB. There 
are insufficient animal and human safety data relating to the 
use of para-aminosalicylic acid (PAS) in pregnancy. It has been 
associated with a slightly higher incidence of limb and ear 
abnormalities in one report involving 123 patients taking PAS 
with other anti-TB drugs [21]. PAS should not be used to treat 
TB in pregnant women unless the benefit/risk ratio is favorable. 
Ethionamide and prothionamide been shown to be teratogenic in 
animal studies and their use is contraindicated in pregnancy.
Breast Feeding
The first-line anti-TB drugs cross into breast milk in variable 
amounts. Rifampicin is excreted into breast milk with milk to 
plasma ratio of 0.2. The amount transferred to the infant (0.05% 
of maternal dose) does not cause adverse effects. Pyrazinamide 
excretion into breast milk is minimal with a maximum of 0.3% 
of the ingested dose reaching the infant [22]. Ethambutol is 
secreted into breast milk with approximate milk to serum ratio 
of 1:1. All these anti-TB drugs are thought to be compatible with 
breastfeeding by pediatric groups such as the American Academy 
of Pediatrics [23].
CONCLUSION
Untreated TB disease presents a greater risk to a pregnant 
woman and her fetus. Treatment should be initiated whenever the 
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probability of TB is moderate to high. Treatment of non-MDR 
patients should be treated by the same regimen as nonpregnant 
patients except the use of streptomycin. A pregnant lady with 
MDR-TB should be advised to terminate the pregnancy. If a 
woman insists on its continuation, the proper communication 
made about consequences before putting on treatment.
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